OptimizeRx (OPRX) stock price, revenue, and financials

OptimizeRx market cap is $539.1 m, and annual revenue was $61.29 m in FY 2021
View Company

$539.1 M

OPRX Mkt cap, 24-Jun-2022

$13.7 M

OptimizeRx Revenue Q1, 2022
OptimizeRx Gross profit (Q1, 2022)8.1 M
OptimizeRx Gross profit margin (Q1, 2022), %59%
OptimizeRx Net income (Q1, 2022)-3.8 M
OptimizeRx EBIT (Q1, 2022)-3.8 M
OptimizeRx Cash, 31-Mar-202289 M
OptimizeRx EV450.5 M
Get notified regarding key financial metrics and revenue changes at OptimizeRxLearn more
Banner background

OptimizeRx Revenue

OptimizeRx revenue was $61.29 m in FY, 2021 which is a 41.5% year over year increase from the previous period.

Embed Graph

OptimizeRx Revenue Breakdown

Embed Graph

OptimizeRx revenue breakdown by business segment: 96.3% from Life Science Companies and 3.7% from Other

OptimizeRx Income Statement

Annual

USDFY, 2019FY, 2020FY, 2021

Revenue

24.6m43.3m61.3m

Revenue growth, %

42%

Cost of goods sold

9.2m19.2m25.7m

Gross profit

15.4m24.1m35.6m

Gross profit Margin, %

63%56%58%

General and administrative expense

15.6m21.0m27.7m

Operating expense total

19.1m26.2m35.3m

Depreciation and amortization

1.3m2.1m2.1m

EBIT

(3.7m)(2.1m)361.1k

EBIT margin, %

(15%)(5%)1%

Interest income

288.0k68.6k17.0k

Pre tax profit

(4.0m)(2.2m)378.1k

Income tax expense

(898.0k)

Net Income

(3.1m)(2.2m)378.1k

EPS

(0.2)(0.1)0.0

Quarterly

USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

7.6m8.8m10.5m11.2m13.6m16.1m13.7m

Cost of goods sold

3.2m3.6m4.5m5.1m5.6m7.0m5.6m

Gross profit

4.3m5.1m6.0m6.1m8.0m9.1m8.1m

Gross profit Margin, %

57%59%57%55%59%56%59%

Operating expense total

6.6m6.2m6.2m6.8m7.7m9.0m11.9m

EBIT

(2.3m)(1.1m)(176.7k)(638.3k)340.1k38.2k(3.8m)

EBIT margin, %

(30%)(12%)(2%)(6%)2%0%(27%)

Interest income

55.3k8.3k4.2k931.012.0k1.7k3.0

Pre tax profit

(2.2m)(1.1m)(282.9k)(637.4k)352.1k39.9k(3.8m)

Net Income

(2.2m)(1.1m)(282.9k)(637.4k)352.1k39.9k(3.8m)

EPS

(0.1)(0.1)0.00.00.0(0.2)

OptimizeRx Balance Sheet

Annual

USDFY, 2019FY, 2020FY, 2021

Cash

18.9m10.5m84.7m

Accounts Receivable

7.4m17.9m24.8m

Prepaid Expenses

871.0k4.5m5.6m

Current Assets

27.1m32.9m115.1m

PP&E

176.0k148.9k143.8k

Goodwill

14.7m14.7m14.7m

Total Assets

56.6m60.3m141.0m

Accounts Payable

493.0k618.3k606.8k

Short-term debt

115.4k123.2k91.0k

Current Liabilities

6.1m10.0m9.4m

Long-term debt

448.8k325.5k236.7k

Non-Current Liabilities

5.7m325.5k236.7k

Total Debt

564.2k448.8k327.7k

Total Liabilities

11.8m10.4m9.6m

Common Stock

14.6k15.2k17.9k

Additional Paid-in Capital

78.3m85.6m166.6m

Retained Earnings

(33.4m)(35.6m)(35.3m)

Total Equity

44.9m50.0m131.4m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.3 x1.2 x1.1 x

Quarterly

USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

15.2m14.1m12.0m82.3m83.9m85.1m89.0m

Accounts Receivable

9.1m10.8m13.3m14.7m17.9m20.7m19.1m

Prepaid Expenses

3.0m2.7m1.9m3.5m3.1m2.6m4.6m

Current Assets

27.3m27.6m27.2m100.5m105.0m108.4m112.7m

PP&E

170.1k156.6k151.8k142.1k137.8k130.9k137.4k

Goodwill

14.7m14.7m14.7m14.7m14.7m14.7m14.7m

Total Assets

56.2m56.1m55.1m127.6m131.6m134.7m138.1m

Accounts Payable

548.1k496.7k480.5k499.3k805.5k771.6k600.7k

Short-term debt

117.5k119.5k121.6k119.4k110.3k101.1k87.6k

Current Liabilities

9.5m12.2m8.1m5.4m6.7m7.6m6.9m

Long-term debt

418.4k387.7k356.6k305.0k282.9k260.6k212.9k

Non-Current Liabilities

3.1m387.7k356.6k305.0k282.9k260.6k212.9k

Total Debt

535.9k507.2k478.2k424.4k393.2k361.7k300.5k

Total Liabilities

12.6m12.6m8.5m5.7m6.9m7.8m7.1m

Common Stock

14.6k14.8k15.1k17.3k17.5k17.7k17.9k

Additional Paid-in Capital

79.2m80.2m83.7m158.1m160.6m162.7m170.0m

Retained Earnings

(35.6m)(36.7m)(37.0m)(36.3m)(35.9m)(35.9m)(39.0m)

Total Equity

43.6m43.5m46.7m121.8m124.7m126.8m131.1m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.2 x1 x1.1 x1.1 x1.1 x

OptimizeRx Cash Flow

Annual

USDFY, 2019FY, 2020FY, 2021

Net Income

(3.1m)(2.2m)378.1k

Depreciation and Amortization

1.3m2.0m2.0m

Accounts Receivable

(628.8k)(10.7m)(7.0m)

Accounts Payable

(46.2k)125.3k(11.4k)

Cash From Operating Activities

(1.7m)(6.3m)726.0k

Purchases of PP&E

(87.7k)(68.0k)(100.3k)

Cash From Investing Activities

(10.6m)(124.7k)(486.0k)

Cash From Financing Activities

22.2m(1.9m)73.9m

Net Change in Cash

9.9m(8.3m)74.2m

Quarterly

USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(2.2m)(3.3m)(3.6m)(637.4k)(285.3k)(245.4k)(3.8m)

Depreciation and Amortization

519.7k1.0m1.6m526.2k1.1m1.6m471.5k

Accounts Receivable

(1.6m)(3.4m)(6.0m)3.1m(88.2k)(2.9m)5.6m

Accounts Payable

55.1k3.7k(12.5k)(119.0k)187.2k153.4k(6.1k)

Cash From Operating Activities

(3.7m)(3.6m)(3.7m)1.7m1.9m2.1m4.1m

Purchases of PP&E

(15.9k)(25.0k)(45.3k)(19.9k)(43.7k)(62.6k)(14.5k)

Cash From Investing Activities

(15.9k)(25.0k)(45.3k)(84.6k)(220.5k)(387.0k)(65.8k)

Cash From Financing Activities

112.2k(1.1m)(3.1m)70.2m71.8m72.9m258.1k

Net Change in Cash

(3.6m)(4.7m)(6.8m)71.8m73.4m74.5m4.3m

OptimizeRx Ratios

USDFY, 2019

EV/EBIT

-35.5 x

EV/CFO

-79 x

Revenue/Employee

351.4k

Financial Leverage

1.3 x

P/E Ratio

(44.7)
View OptimizeRx profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more